Kalantar-Zadeh Kamyar, Regidor Deborah L, Kovesdy Csaba P, Van Wyck David, Bunnapradist Suphamai, Horwich Tamara B, Fonarow Gregg C
Harold Simmons Center for Kidney Disease Research and Epidemiology, Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, 1124 W Carson St, C1-Annex, Torrance, CA 90509-2910, USA.
Circulation. 2009 Feb 10;119(5):671-9. doi: 10.1161/CIRCULATIONAHA.108.807362. Epub 2009 Jan 26.
Patients with chronic kidney disease (stage 5) who undergo hemodialysis treatment have similarities to heart failure patients in that both populations retain fluid frequently and have excessively high mortality. Volume overload in heart failure is associated with worse outcomes. We hypothesized that in hemodialysis patients, greater interdialytic fluid gain is associated with poor all-cause and cardiovascular survival.
We examined 2-year (July 2001 to June 2003) mortality in 34,107 hemodialysis patients across the United States who had an average weight gain of at least 0.5 kg above their end-dialysis dry weight by the time the subsequent hemodialysis treatment started. The 3-month averaged interdialytic weight gain was divided into 8 categories of 0.5-kg increments (up to > or =4.0 kg). Eighty-six percent of patients gained >1.5 kg between 2 dialysis sessions. In unadjusted analyses, higher weight gain was associated with better nutritional status (higher protein intake, serum albumin, and body mass index) and tended to be linked to greater survival. However, after multivariate adjustment for demographics (case mix) and surrogates of malnutrition-inflammation complex, higher weight-gain increments were associated with increased risk of all-cause and cardiovascular death. The hazard ratios (95% confidence intervals) of cardiovascular death for weight gain <1.0 kg and > or =4.0 kg (compared with 1.5 to 2.0 kg as the reference) were 0.67 (0.58 to 0.76) and 1.25 (1.12 to 1.39), respectively.
In hemodialysis patients, greater fluid retention between 2 subsequent hemodialysis treatment sessions is associated with higher risk of all-cause and cardiovascular death. The mechanisms by which fluid retention influences cardiovascular survival in hemodialysis may be similar to those in patients with heart failure and warrant further research.
接受血液透析治疗的慢性肾脏病(5期)患者与心力衰竭患者有相似之处,即这两类人群经常出现体液潴留且死亡率极高。心力衰竭中的容量超负荷与更差的预后相关。我们推测,在血液透析患者中,透析间期更大的体液增加量与全因死亡率及心血管死亡率升高有关。
我们研究了美国34107例血液透析患者的2年(2001年7月至2003年6月)死亡率,这些患者在下一次血液透析治疗开始时,平均体重较透析结束时的干体重增加至少0.5kg。将3个月的平均透析间期体重增加量分为8类,以0.5kg为增量(最高至≥4.0kg)。86%的患者在两次透析之间体重增加超过1.5kg。在未经调整的分析中,体重增加较多与更好的营养状况(更高的蛋白质摄入量、血清白蛋白和体重指数)相关,且往往与更高的生存率有关。然而,在对人口统计学特征(病例组合)和营养不良-炎症复合体指标进行多变量调整后,更高的体重增加量与全因死亡和心血管死亡风险增加相关。体重增加<1.0kg和≥4.0kg时心血管死亡的风险比(95%置信区间)(以1.5至2.0kg作为参照)分别为0.67(0.58至0.76)和1.25(1.12至1.39)。
在血液透析患者中,两次连续血液透析治疗之间更大的体液潴留与全因死亡和心血管死亡的更高风险相关。体液潴留影响血液透析患者心血管生存的机制可能与心力衰竭患者相似,值得进一步研究。